A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting
Location: See all (22) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY
The purpose of this study is to evaluate the preliminary safety and determine the RP2D of mezigdomide in combination with elranatamab in participants with relapsed and refractory multiple myeloma (RRMM).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age ≥18 with history of relapsed and refractory multiple myeloma (RRMM) treated with 2 to 4 prior lines of anti-myeloma therapy (Phase 1) or 1 to 3 prior lines of anti-myeloma therapy (Phase 2).
• Measurable MM by local laboratory.
• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
• Adherence to contraception requirements.
Locations
United States
Alabama
University of Alabama at Birmingham
RECRUITING
Birmingham
Connecticut
Yale New Haven Hospital-Smilow Cancer Center
RECRUITING
New Haven
New Jersey
Hackensack University Medical Center
RECRUITING
Hackensack
Texas
University of Texas MD Anderson Cancer Center
RECRUITING
Houston
Other Locations
Canada
Arthur J E Child Comprehensive Cancer Centre
RECRUITING
Calgary
Local Institution - 0027
NOT_YET_RECRUITING
Halifax
Princess Margaret Cancer Centre
RECRUITING
Toronto
Local Institution - 0026
NOT_YET_RECRUITING
Vancouver
China
Local Institution - 0031
NOT_YET_RECRUITING
Shanghai
Local Institution - 0030
NOT_YET_RECRUITING
Suzhou
Germany
Universitaetsklinikum Carl Gustav Carus Dresden
RECRUITING
Dresden
Universitaetsklinikum Hamburg-Eppendorf
RECRUITING
Hamburg
Universitaetsklinikum Heidelberg
RECRUITING
Heidelberg
Greece
Alexandra General Hospital of Athens
RECRUITING
Athens
Evangelismos General Hospital of Athens
RECRUITING
Athens
Norway
Sykehusapoteket Ull
RECRUITING
Oslo
St. Olavs Hospital
RECRUITING
Trondheim
Spain
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
RECRUITING
Salamanca
Hospital Universitario Marqués de Valdecilla
RECRUITING
Santander
United Kingdom
Royal Marsden Hospital (Sutton)
RECRUITING
London
University College London Hospital
RECRUITING
London
The Christie NHS Foundation Trust
RECRUITING
Manchester
Contact Information
Primary
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Clinical.Trials@bms.com
855-907-3286
Backup
First line of the email MUST contain the NCT# and Site #.
Time Frame
Start Date: 2025-10-07
Estimated Completion Date: 2027-06-03
Participants
Target number of participants: 62
Treatments
Experimental: Phase 1
Experimental: Phase 2
Related Therapeutic Areas
Sponsors
Leads: Celgene